Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (761)

1

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer : Phase III ERMES Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Pinto, C. | Orlandi, A. | Normanno, N. | +17

2

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer : a multicenter, open-label, randomized, controlled, phase 3 trial

enthalten in: Signal transduction and targeted therapy | 2024

von Pan, Q. | Zhao, J. | Liu, L. | +27

3

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma : A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von De La Fouchardière, C. | Malka, D. | Cropet, C. | +23

4

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer : Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Lorenzen, S. | Götze, T. | Thuss-Patience, P. | +24

5

A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer : The AGENT Trial

enthalten in: Cancer research communications | 2024

von Tabernero, J. | Yoshino, T. | Stintzing, S. | +8

6

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19) : quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial

enthalten in: The Lancet. Oncology | 2023

von Velikova, G. | Morden, J. | Haviland, J. | +15

ErratumIn: Lancet Oncol. 2023 Dec;24(12):e459. - PMID 38040001

7

Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma : long-term results of a phase III randomized controlled trial

enthalten in: International journal of surgery (London, England) | 2023

von Tian, Y. | Yang, P. | Guo, H. | +14

8

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS) : an open-label, randomised, phase 3 trial

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Reynolds, J. | Preston, S. | O'Neill, B. | +52

9

A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)

enthalten in: Cancer research and treatment | 2023

von Lee, K. | Zang, D. | Ryu, M. | +12

10

Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)

enthalten in: Breast cancer research and treatment | 2023

von Hwang, I. | Kim, J. | Jeong, J. | +8

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[77]